Enlight emphasizes on areas including molecular imaging, biologics, drug formulation delivery methods, besides novel chemistries, production technologies, biomarkers and drug safety.
Enlight CEO Michelle Browner said the company hopes to benefit from contributions of AstraZeneca and Novo Nordisk.
AstraZeneca Innovative Medicines Executive Vice President Menelas Pangalos said Enlight would provide an opportunity for its biologics arm, MedImmune, to support the development of tools that will improve R&D across the industry.